Canada-based cell and gene therapy contract development and manufacturing organization (CDMO) uBriGene is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from US cell and gene therapy specialist Mustang Bio (Nasdaq: MBIO).
Financial terms of the deal were not disclosed, but Mustang’s shares were down 2.6% at $4.10 by mid-morning.
The CDMO has an established global footprint with two GMP manufacturing facilities in China and its headquarters in Vancouver, Canada. The latest move will see uBriGene expand its global headcount to over 500 employees.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze